BioCentury on BioBusiness,
Emerging Company Profile
CBS's inhibitors could synergize with metastatic colorectal cancer therapies
Related tables, figures and sidebars
CBS: Sniffing out cancer therapy
Monday, March 3, 2014
Therapeutics Inc. is developing first-in-class inhibitors of
cystathionine beta synthase that could synergize with existing therapies to
treat both KRAS-mutant and wild-type metastatic colorectal cancer.
Cystathionine beta synthase
(CBS) is found in many cell types and metabolizes the amino acid homocysteine
to cystathionine by two different routes. One route produces hydrogen sulfide,
a gas involved in normal vasorelaxation, angiogenesis and energy production.
While studies have shown exogenous hydrogen sulfide promotes growth in cancer
cell lines, the roles of endogenously produced hydrogen sulfide and CBS in
cancer were undefined.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]